Glaxo Buys A Stake In Intercell And Gains Access To Patch Vaccine Techology
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of the deal, the big drug maker gets the right to market experimental patch vaccines for traveler's diarrhea and pandemic flu.
You may also be interested in...
Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.
Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.